14300-71-1Relevant academic research and scientific papers
Scope and limitations of the photooxidations of 2-(α-Hydroxyalkyl) furans: Synthesis of 2-hydroxy-exo -brevicomin
Noutsias, Dimitris,Kouridaki, Antonia,Vassilikogiannakis, Georgios
supporting information; experimental part, p. 1166 - 1169 (2011/05/06)
Photooxygenation of 2-(α-hydroxyalkyl)furans at 5 °C in MeOH followed by in situ reduction affords, in one synthetic operation, 6-hydroxy-3(2H)-pyranones and/or 5-hydroxy-2(5H)-furanones. The relative ratio of the final products is highly dependent on the substitution of the starting furan substrate. Photooxygenation of 2-(α,β-dihydroxyalkyl)furans followed by in situ reduction and ketalization with acid rapidly provides the 6,8-dioxabicyclo[3.2.1]oct-3-en-2-one framework. This new methodology was successfully applied to the synthesis of 2-hydroxy-exo-brevicomin.(Figure Presented)
Highly efficient continuous flow reactions using singlet oxygen as a "Green" reagent
Levesque, Francois,Seeberger, Peter H.
supporting information; experimental part, p. 5008 - 5011 (2011/12/04)
Described is a new method for the efficient in situ production of singlet oxygen in a simple continuous flow photochemical reactor. The extremely large interfacial area generated by running the biphasic mixture in a narrow channel at a high flow rate ensures high throughput as well as fast and efficient oxidation of various alkenes, 1,3-dienes, and thioethers on a preparative scale.
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
-
, (2008/06/13)
The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
